Mice infected with Mycobacterium bovis, BCG, were shown to be highly susceptible to subsequent challenge with Pspdomonas aeruginosa. The susceptibility was characterized by the enhanced mortality and shoptened survival afteq challenge with P. aeruginosa. BCG-treated mice did not show any enhanaed susceptibility to challenge with Gram-positive bacteria such as Staphylococcus aureus or Liskria monocytogenes. BCG-treated mice eliminated P . aeruginosa from their organs in a pattqrn similar to that in untreated mice. There was no significant difference in the bactericidal activities of polymorphonuclear cells and macrophages between BCG-treated and untreated mice. An equal amount of endotoxin was detected by the Limulus lysate assay in the blood of both BCG-treated and untreated mice after challenge with P . aeruginosa. The enhanced susceptibility induced by BCG pretreatment could be decreased when the mice were rendered LPS-tolerant by injections of small amounts of LPS. These results suggest that BCG-induced slusceptibility to P . Qeruginosa can be ascribed to an enhanced susceptibility to the lethal qffect of LPS produced by challenge bacteria, and not to the impairment of the ability to eliminate infected bacteria.
INTRODUCTION
Pseudomoms aeruginosa is one of the most important causes of nosocomial infections (Benett 1974; Reinarz et al., 1979) and lethal infections in burned and other compromised hosts (Peavy et aZ., 1979; Reynolds et al., 1975) . In addition to chemotherapy with antibiotics, two approaches have been used to control pseudomonas infection. One major approach was immunization with vaccine obtained from P . aeruginosa, and satisfactory results were obtained in some animal models (Pier et al., 1978; Liebermann et al., 1980) . Another approach may be to find agents capable of augmenting non-specific resistance against P. aeruginosa, since Corynebacterium parvum (Miyata et al., 1980) , Mycobacterium bovis strain BCG (Matsuo et al., 1977) or muramyl dipeptide (Chedid & Parant, 1971; Matsumoto et al., 1981) have been reported to increase non-specific resistance against several kinds of bacterial infections. Treatment with complete Freund's adjuvant or BCG restores the resistance against P . aeruginosa in granulocytopenic mice (Buhles & Shiferine, 1977) . The resistance of normal mice against primary infection with P . aeruginosa seems to be attributable mainly to polymorphonuclear cells (PMN) but not to macrophages (Tatsukawa et al., 1979) . On the other hand, complete Freund's adjuvant and BCG have been shown to activate mainly the functions of macrophages. In the present study, which was carried out to determine the effect of BCG treatment in normal mice, it was found that BCG treatment did not augment the resistance but rather enhanced a lethal effect of pseudomonas infection. In addition such BCG treatment augmented the resistance against Listeria monocytogenes to which resistance had been reported to depend mainly upon the function of macrophages (Tatsukawa et al., 1979) .
Groups of mice treated with BCG or untreated were challenged i.v. with various doses of P.
aeruginosa. The LD,, of P . aeruginosa by the i.v. route in normal mice was 3 x lo6 c.f.u. Some of untreated control mice died on day 4 or 5 after challenge with 3 x lo6 c.f.u. of bacteria. Mice treated with BCG before challenge showed a very high mortality irrespective of the time between BCG treatment and challenge ( Table 1) . In mice treated with BCG, 100% mortality was recorded after challenge with 1.8 x lo6 c.f.u., while 80% of untreated mice survived this challenge dose. Moreover, death of mice treated with BCG was observed within 1 d after challenge in most cases. It is evident from these results that BCG enhances the susceptibility of mice to challenge with P . aeruginosa. Such an enhanced susceptibility was also observed when the challenge was by the i.p. or i.m. route. E_tTect of BCG pretreatment on the susceptibility to challenge with P . aeruginosa in athymic nude mice and euthymic littermates To determine whether cell-mediated immunity against BCG contributed to the enhanced susceptibility to pseudomonas challenge, athymic nude mice of BALB/C background were used. Athymic nude mice and heterozygous euthymic littermates were treated with BCG, and challenged with 1 or 5 x lo6 P. aeruginosa 2 weeks after BCG treatment. It was observed that all of the mice treated with BCG died within 1 d after challenge with P. aeruginosa. There was no difference in the pattern of death between nu/+ and nu/nu mice. It was apparent that cellmediated immunity against BCG did not contribute to the enhancement of susceptibility to P . aeruginosa.
Efleect of BCG treatment on the susceptibility to infection with Gram-positive bacteria
To observe the effect of BCG treatment on the resistance or susceptibility to Gram-positive bacteria, S . aureus and L. monocytogenes, were used for challenge. There was no significant difference in the mortality between untreated mice and mice treated with BCG 2 weeks before the challenge with S. aureus ( Table 2) .
When the challenge was done with L. monocytogenes, the mortality was reduced in mice treated with BCG.
Enumeration of P . aeruginosa in untreated mice or mice treated with BCG There was a possibility that the BCG-induced susceptibility to challenge with P . aeruginosa was due to enhanced bacterial growth in BCG-treated mice. To clarify this, the number of bacteria in thigh muscle inoculated with 1-5 x lo5 P . aeruginosa was counted 5,24 and 48 h after the challenge. In both groups of BCG-treated or untreated mice, the number of organisms decreased continuously for 48 h (Fig. 1) . With this challenge dose and route, no death was observed in either group of mice. As a follow up to this experiment bacterial counts in organs were compared from untreated and BCG-treated mice after an i.v. challenge with 1 x lo6 bacteria several hours after challenge. Most of the BCG-treated mice became ill 10 h after challenge, and they were sacrificed along with control mice. -The counts of bacteria in the spleen, liver, kidney and blood were enumerated. Data from two typical experiments revealed that the growth of bacteria in BCG-treated mice was similar to that in control mice. Thus BCG-induced susceptibility could not be attributed to enhanced growth of the challenge bacteria. Next, bactericidal activity of macrophages and PMN was examined in vitro according to the method described by Van Furth & Van Zwet (1973) . Results from three experiments showed that 80% of the bacteria phagocytosed by phagocytes from BCG-treated or untreated mice were killed during 60min in vitro incubation. No significant difference was found in the killing activities of macrophages or PMN between BCG-treated and untreated mice.
Challenge of mice with killed bacteria Killed bacteria were used in the challenge dose to check whether viability is required for P . aeruginosa to express its lethal effect in BCG-treated mice. Bacteria were killed by heating half of the bacterial suspension at 70°C for 30min. The remaining suspension was used for the viable challenge and contained 4.7 x lo6 c.f.u. ml-l. Mice treated with BCG 2 weeks previously were challenged i.v. with 4.7 x lo6 viable or killed organisms. In the untreated group of mice, this dose of viable bacteria caused 60% deaths and the mean survival time was 4.5 d ; inoculation of 4.7 x lo6 heat-killed bacteria did not cause death in untreated mice. If mice were treated with BCG 2 weeks before challenge, all mice died and there was a shortened survival time after challenge with killed bacteria. It was apparent that the enhanced mortality in BCGtreated mice was not due to enhanced bacterial growth or the lethal effect of P . aeruginosa exotoxin but to potentiation of a factor associated with killed organisms.
Assay of endotoxin in plasma of mice after challenge with P . aeruginosa Pseudomonas aeruginosa possesses endotoxin in the cell wall and the possibility existed that the enhanced mortality might be attributable to the lethal effect of this endotoxin. To test this, the level of endotoxin in plasma was studied using the Limulus test. Plasma was obtained 6 h after challenge with 3 x lo6 P. aeruginosa from BCG-treated or untreated mice. In each case positive Limulus tests were observed in plasma diluted 1 in 2000; there was no evidence for greater quantities of endotoxin in BCG-treated mice.
Susceptibility of BCG-treated mice to lethal effect of LPS
It has been reported that BCG-treated mice showed an enhanced susceptibility to the lethal effect of LPS (Howard et al., 1959; Suter et al., 1958) . BCG-induced susceptibility to P . aeruginosa might be attributed to enhanced susceptibility of mice to bacterial LPS. Various doses of LPS from P . aeruginosa were injected i.p. into BCG-treated or untreated mice, and the mortality was measured. LPS in doses up to 100 pg was not lethal to untreated mice. However, mice treated with BCG showed a striking increase in susceptibility to LPS. Even with 10 pg LPS, all BCG-treated mice died within 1 d; similar results were obtained in three experiments.
Eflect of tolerance induction against LPS on BCG-induced susceptibility to LPS Tolerance of mice against pseudomonas LPS (LPS tolerance) was established by repeated injections of very small doses of LPS into mice. A dose of 10 pg LPS was lethal for BCG-treated mice, all mice (lO/lO) dying within 1 d. On the other hand no deaths occurred in BCG-treated mice that received the same dose of LPS after being made tolerant to LPS: indeed 8/10 tolerant mice even survived the injection of 25 pg LPS. In LPS-tolerant BCG-treated mice 7/10 animals survived the challenge with 3 x lo6 viable P. aeruginosa. Similar results were obtained in repeat experiments.
DISCUSSION
Mice treated with BCG showed an enhanced susceptibility to P . aeruginosa. This BCGinduced susceptibility, which was characterized by an increased mortality and a shortened survival time, was observed as early as 1 week after BCG treatment. The results obtained in this study demonstrated that BCG-induced susceptibility to P . aeruginosa was not due to any impairment of the ability to eliminate bacteria, but was probably due to an enhanced susceptibility to bacterial endotoxin.
LPS produces a variety of biological effects in experimental animals, including hypothermia, leucopenia and death. In mice challenged with P. aeruginosa, it is to be expected that the bacteria will be phagocytosed and digested. In the course of degradation of bacterial cells it is likely that LPS will be released into the circulation. In our study there were no changes in the kinetics of bacterial elimination or in bactericidal activity of phagocytes in BCG-treated mice as compared with those in untreated mice. Therefore, enhanced or rapid release of a greater amount of LPS in BCG-treated mice can be excluded. Results with the Limulus test indicated that the amount of LPS in the circulation was not affected by BCG treatment.
It seems likely then that enhanced susceptibility of BCG-treated mice to P . aeruginosa resembles BCG-induced hyperreactivity to LPS reported by Suter et al. (1958) . BCG-induced hyperreactivity was expressed only against the lethal effect of LPS and not against the pyrogenic effect or skin-necrotizing effect (Suter, 1964) . In spite of extensive studies on this phenomenon, the precise mechanism for it has not been elucidated. In recent years, prostaglandin has been regarded as an important mediator of endotoxin action (Rietschel et al., 1980) , but it is not clear whether the lethal effect of LPS is mediated only by this substance. Macrophages are reported to synthesize and release prostaglandins after stimulation with LPS. BCG-induced peritoneal macrophages are also reported to release a large amount of prostaglandins, so that one possibility is that BCG-induced hyperreactivity to a lethal effect is due to some synergistic effect of BCG and LPS on the release of prostaglandins by macrophages. An alternative possibility may be the destruction of macrophages and release of some vasoactive substances from them. This possibility is supported by a report showing that LPS caused a dose-dependent decrease in the survival of macrophages from BCG-treated mice (Peavy et al., 1979) . In any case, the precise mechanism of BCG-induced hyperreactivity to LPS should be clarified in the future.
In conclusion, our findings on BCG-induced enhancement of death against pseudomonas infection should be taken into consideration in relation to the use of BCG as an immunomodulator.
The technical assistance of Dr Sachio Sumita (Fukuoka Central Hospital) in the Limulus test is gratefully acknowledged.
